|
1
|
Jemal A, Siegel R, Ward E, Murray T, Xu J,
Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin.
56:106–130. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bond-Smith G, Banga N, Hammond TM and
Imber CJ: Pancreatic adenocarcinoma. BMJ. 344:e24762012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Merl MY, Abdelghany O, Li J and Saif MW:
First-line treatment of metastatic pancreatic adenocarcinoma: Can
we do better? Highlights from the '2010 ASCO Annual Meeting'.
Chicago, IL, USA. June 4–8, 2010. JOP. 11:317–320. 2010.PubMed/NCBI
|
|
4
|
Kindler HL: Front-line therapy of advanced
pancreatic cancer. Semin Oncol. 32(Suppl 9): S33–S36. 2005.
View Article : Google Scholar
|
|
5
|
Gonzalez-Angulo AM, Morales-Vasquez F and
Hortobagyi GN: Overview of resistance to systemic therapy in
patients with breast cancer. Adv Exp Med Biol. 608:1–22. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gottesman MM and Pastan IH: The role of
multidrug resistance efflux pumps in cancer: Revisiting a JNCI
publication exploring expression of the MDR1 (P-glycoprotein) gene.
J Natl Cancer Inst. 107:1072015. View Article : Google Scholar
|
|
7
|
Radin D, Lippa A, Patel P and Leonardi D:
Lifeguard inhibition of Fas-mediated apoptosis: A possible
mechanism for explaining the cisplatin resistance of
triple-negative breast cancer cells. Biomed Pharmacother.
77:161–166. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ojini I and Gammie A: Rapid identification
of chemoresistance mechanisms using yeast DNA mismatch repair
mutants. G3 (Bethesda). 5:1925–1935. 2015. View Article : Google Scholar
|
|
9
|
Aldinucci D, Celegato M and Casagrande N:
Microenvironmental interactions in classical Hodgkin lymphoma and
their role in promoting tumor growth, immune escape and drug
resistance. Cancer Lett. 380:243–252. 2016. View Article : Google Scholar
|
|
10
|
Mastri M, Rosario S, Tracz A, Frink RE,
Brekken RA and Ebos JM: The challenges of modeling drug resistance
to antiangiogenic therapy. Curr Drug Targets. 17:1747–1754. 2016.
View Article : Google Scholar
|
|
11
|
Gottesman MM: Mechanisms of cancer drug
resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ren D, Wang M, Guo W, Huang S, Wang Z,
Zhao X, Du H, Song L and Peng X: Double-negative feedback loop
between ZEB2 and miR-145 regulates epithelial-mesenchymal
transition and stem cell properties in prostate cancer cells. Cell
Tissue Res. 358:763–778. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ren D, Wang M, Guo W, Zhao X, Tu X, Huang
S, Zou X and Peng X: Wild-type p53 suppresses the
epithelial-mesenchymal transition and stemness in PC-3 prostate
cancer cells by modulating miR 145. Int J Oncol. 42:1473–1481.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li X, Jin Y, Mu Z, Chen W and Jiang S:
MicroRNA 146a 5p enhances cisplatin induced apoptosis in ovarian
cancer cells by targeting multiple anti apoptotic genes. Int J
Oncol. 51:327–335. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Feng C, Sun P, Hu J, Feng H, Li M, Liu G,
Pan Y, Feng Y, Xu Y, Feng K, et al: miRNA-556-3p promotes human
bladder cancer proliferation, migration and invasion by negatively
regulating DAB2IP expression. Int J Oncol. 50:2101–2112. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang X, Liu J, Zang D, Wu S, Liu A, Zhu
J, Wu G, Li J and Jiang L: Upregulation of miR-572
transcriptionally suppresses SOCS1 and p21 and contributes to human
ovarian cancer progression. Oncotarget. 6:15180–15193.
2015.PubMed/NCBI
|
|
18
|
Ren D, Yang Q, Dai Y, Guo W, Du H, Song L
and Peng X: Oncogenic miR-210-3p promotes prostate cancer cell EMT
and bone metastasis via NF-κB signaling pathway. Mol Cancer.
16:1172017. View Article : Google Scholar
|
|
19
|
Guo W, Ren D, Chen X, Tu X, Huang S, Wang
M, Song L, Zou X and Peng X: HEF1 promotes epithelial mesenchymal
transition and bone invasion in prostate cancer under the
regulation of microRNA-145. J Cell Biochem. 114:1606–1615. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chaudhary AK, Mondal G, Kumar V, Kattel K
and Mahato RI: Chemosensitization and inhibition of pancreatic
cancer stem cell proliferation by overexpression of microRNA-205.
Cancer Lett. 402:1–8. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen M, Wang M, Xu S, Guo X and Jiang J:
Upregulation of miR-181c contributes to chemoresistance in
pancreatic cancer by inactivating the Hippo signaling pathway.
Oncotarget. 6:44466–44479. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The Eighth Edition AJCC Cancer Staging Manual:
Continuing to build a bridge from a population-based to a more
'personalized' approach to cancer staging. CA Cancer J Clin.
67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang M, Ren D, Guo W, Huang S, Wang Z, Li
Q, Du H, Song L and Peng X: N-cadherin promotes
epithelial-mesenchymal transition and cancer stem cell-like traits
via ErbB signaling in prostate cancer cells. Int J Oncol.
48:595–606. 2016. View Article : Google Scholar
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
25
|
Hahn WC, Dessain SK, Brooks MW, King JE,
Elenbaas B, Sabatini DM, DeCaprio JA and Weinberg RA: Enumeration
of the simian virus 40 early region elements necessary for human
cell transformation. Mol Cell Biol. 22:2111–2123. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang X, Ren D, Guo L, Wang L, Wu S, Lin
C, Ye L, Zhu J, Li J, Song L, et al: Thymosin beta 10 is a key
regulator of tumorigenesis and metastasis and a novel serum marker
in breast cancer. Breast Cancer Res. 19:152017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ren D, Lin B, Zhang X, Peng Y, Ye Z, Ma Y,
Liang Y, Cao L, Li X, Li R, et al: Maintenance of cancer stemness
by miR-196b-5p contributes to chemoresistance of colorectal cancer
cells via activating STAT3 signaling pathway. Oncotarget.
8:49807–49823. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cheadle C, Vawter MP, Freed WJ and Becker
KG: Analysis of microarray data using Z score transformation. J Mol
Diagn. 5:73–81. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Betel D, Wilson M, Gabow A, Marks DS and
Sander C: The microRNA.org resource: Targets and expression.
Nucleic Acids Res. 36:D149–D153. 2008. View Article : Google Scholar :
|
|
30
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. Aug 12–2015.Epub ahead of print. View Article : Google Scholar
|
|
31
|
Zhang X, Zhang L, Lin B, Chai X, Li R,
Liao Y, Deng X, Liu Q, Yang W, Cai Y, et al: Phospholipid
phosphatase 4 promotes proliferation and tumorigenesis, and
activates Ca2+-permeable cationic channel in lung
carcinoma cells. Mol Cancer. 16:1472017. View Article : Google Scholar
|
|
32
|
Li X, Liu F, Lin B, Luo H, Liu M, Wu J, Li
C, Li R, Zhang X, Zhou K, et al: miR 150 inhibits proliferation and
tumorigenicity via retarding G1/S phase transition in
nasopharyngeal carcinoma. Int J Oncol. Mar 10–2017.Epub ahead of
print. View Article : Google Scholar
|
|
33
|
Johnstone RW, Ruefli AA and Lowe SW:
Apoptosis: A link between cancer genetics and chemotherapy. Cell.
108:153–164. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Reed JC: Bcl-2 and the regulation of
programmed cell death. J Cell Biol. 124:1–6. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Reed JC: Dysregulation of apoptosis in
cancer. J Clin Oncol. 17:2941–2953. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ripka S, Neesse A, Riedel J, Bug E, Aigner
A, Poulsom R, Fulda S, Neoptolemos J, Greenhalf W, Barth P, et al:
CUX1: Target of Akt signalling and mediator of resistance to
apoptosis in pancreatic cancer. Gut. 59:1101–1110. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Deveraux QL, Takahashi R, Salvesen GS and
Reed JC: X-linked IAP is a direct inhibitor of cell-death
proteases. Nature. 388:300–304. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mendoza-Rodríguez M, Arévalo Romero H,
Fuentes-Pananá EM, Ayala-Sumuano JT and Meza I: IL-1β induces
up-regulation of BIRC3, a gene involved in chemoresistance to
doxorubicin in breast cancer cells. Cancer Lett. 390:39–44. 2017.
View Article : Google Scholar
|
|
39
|
Cillessen SA, Reed JC, Welsh K, Pinilla C,
Houghten R, Hooijberg E, Deurhof J, Castricum KC, Kortman P, Hess
CJ, et al: Small-molecule XIAP antagonist restores caspase-9
mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma
cells. Blood. 111:369–375. 2008. View Article : Google Scholar
|
|
40
|
Fakler M, Loeder S, Vogler M, Schneider K,
Jeremias I, Debatin KM and Fulda S: Small molecule XIAP inhibitors
cooperate with TRAIL to induce apoptosis in childhood acute
leukemia cells and overcome Bcl-2-mediated resistance. Blood.
113:1710–1722. 2009. View Article : Google Scholar
|
|
41
|
Kashkar H, Deggerich A, Seeger JM,
Yazdanpanah B, Wiegmann K, Haubert D, Pongratz C and Krönke M:
NF-kappaB-independent down-regulation of XIAP by bortezomib
sensitizes HL B cells against cytotoxic drugs. Blood.
109:3982–3988. 2007. View Article : Google Scholar
|
|
42
|
Kater AP, Dicker F, Mangiola M, Welsh K,
Houghten R, Ostresh J, Nefzi A, Reed JC, Pinilla C and Kipps TJ:
Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic
leukemia cells to CD95-mediated apoptosis. Blood. 106:1742–1748.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jones A, Danielson KM, Benton MC, Ziegler
O, Shah R, Stubbs RS, Das S and Macartney-Coxson D: miRNA
signatures of insulin resistance in obesity. Obesity (Silver
Spring). 25:1734–1744. 2017. View Article : Google Scholar
|
|
44
|
Xu HX, Wang Y, Zheng DD, Wang T, Pan M,
Shi JH, Zhu JH and Li XF: Differential expression of microRNAs in
calcific aortic stenosis. Clin Lab. 63:1163–1170. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tan JR, Tan KS, Yong FL, Armugam A, Wang
CW, Jeyaseelan K and Wong PT: MicroRNAs regulating cluster of
differentiation 46 (CD46) in cardioembolic and non-cardioembolic
stroke. PLoS One. 12:e01721312017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hu S, Bao H, Xu X, Zhou X, Qin W, Zeng C
and Liu Z: Increased miR-374b promotes cell proliferation and the
production of aberrant glycosylated IgA1 in B cells of IgA
nephropathy. FEBS Lett. 589:4019–4025. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang C, Yang C, Chen X, Yao B, Yang C, Zhu
C, Li L, Wang J, Li X, Shao Y, et al: Altered profile of seminal
plasma microRNAs in the molecular diagnosis of male infertility.
Clin Chem. 57:1722–1731. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhang K, Wang YW, Wang YY, Song Y, Zhu J,
Si PC and Ma R: Identification of microRNA biomarkers in the blood
of breast cancer patients based on microRNA profiling. Gene.
619:10–20. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chang JT, Wang F, Chapin W and Huang RS:
Identification of microRNAs as breast cancer prognosis markers
through the cancer genome atlas. PLoS One. 11:e01682842016.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hanniford D, Zhong J, Koetz L,
Gaziel-Sovran A, Lackaye DJ, Shang S, Pavlick A, Shapiro R, Berman
R, Darvishian F, et al: A miRNA-based signature detected in primary
melanoma tissue predicts development of brain metastasis. Clin
Cancer Res. 21:4903–4912. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Summerer I, Unger K, Braselmann H,
Schuettrumpf L, Maihoefer C, Baumeister P, Kirchner T, Niyazi M,
Sage E, Specht HM, et al: Circulating microRNAs as prognostic
therapy biomarkers in head and neck cancer patients. Br J Cancer.
113:76–82. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Xie J, Tan ZH, Tang X, Mo MS, Liu YP, Gan
RL, Li Y, Zhang L and Li GQ: MiR-374b-5p suppresses RECK expression
and promotes gastric cancer cell invasion and metastasis. World J
Gastroenterol. 20:17439–17447. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
He HC, Han ZD, Dai QS, Ling XH, Fu X, Lin
ZY, Deng YH, Qin GQ, Cai C, Chen JH, et al: Global analysis of the
differentially expressed miRNAs of prostate cancer in Chinese
patients. BMC Genomics. 14:7572013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Qian D, Chen K, Deng H, Rao H, Huang H,
Liao Y, Sun X, Lu S, Yuan Z, Xie D, et al: MicroRNA-374b suppresses
proliferation and promotes apoptosis in T-cell lymphoblastic
lymphoma by repressing AKT1 and Wnt-16. Clin Cancer Res.
21:4881–4891. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wu X, Li S, Xu X, Wu S, Chen R, Jiang Q,
Li Y and Xu Y: The potential value of miR-1 and miR-374b as
biomarkers for colorectal cancer. Int J Clin Exp Pathol.
8:2840–2851. 2015.PubMed/NCBI
|
|
56
|
Schreiber R, Mezencev R, Matyunina LV and
McDonald JF: Evidence for the role of microRNA 374b in acquired
cisplatin resistance in pancreatic cancer cells. Cancer Gene Ther.
23:241–245. 2016. View Article : Google Scholar : PubMed/NCBI
|
